We represented Sanfer Farma, in the investment and subscription of 310,984,900 shares representing 80% of the capital stock of Probiomed, a Mexican biopharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical health products.
Lead Partner:
Luis A. Nicolau
Other team members:
Eric Silberstein Lerner, Tatiana Canales Cantú, Cecilia Legaspi, Adriana Padilla Rivas
Other Firms advising on the matter and their roles:
CR&F Abogados - Counsel to Probiomed
Zimma Corporate Finance - Counsel to Probiomed
Practices Areas:
Mergers & Acquisitions
Client Name:
Sanfer Farma
Industry:
Pharmaceuticals & Life Sciences
